ST elevation myocardial infarction implantable cardioverter defibrillator: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (/* 2013 ACCF/AHA Guideline for the Management of Heart Failure (DO NOT EDIT){{cite journal| author=Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al.| title=2013 ACCF/AHA guideline for the management of heart failure: executive summar...) |
Rim Halaby (talk | contribs) (/* 2013 ACCF/AHA Guideline for the Management of Heart Failure (DO NOT EDIT){{cite journal| author=Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al.| title=2013 ACCF/AHA guideline for the management of heart failure: executive summar...) |
||
| Line 11: | Line 11: | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class I]] | | colspan="1" style="text-align:center; background:LightGreen"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1. '''ICD therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in selected patients with nonischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for more than 1 year. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1. '''[[Implantable cardioverter-defibrillator]] (ICD) therapy is recommended for primary prevention of [[sudden cardiac death]] to reduce total mortality in selected patients with nonischemic [[dilated cardiomyopathy]] or [[ischemic heart disease]] at least 40 days post-MI with [[LVEF]] of 35% or less and [[NYHA]] class II or III symptoms on chronic guideline-directed medical therapy (GDMT), who have reasonable expectation of meaningful survival for more than 1 year. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2. '''ICD therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in selected patients at least 40 days post-MI with LVEF of 30% or less and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2. '''[[ICD]] therapy is recommended for primary prevention of [[sudden cardiac death]] to reduce total mortality in selected patients at least 40 days post-MI with LVEF of 30% or less and [[NYHA class I]] symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year. ''([[EHS ESC guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|} | |} | ||
| Line 20: | Line 20: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1. '''To prevent sudden death, placement of an | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1. '''To prevent sudden death, placement of an ICD is reasonable in patients with asymptomatic ischemic cardiomyopathy who are at least 40 days post-MI, have an LVEF of 30% or less, are on appropriate medical therapy, and have reasonable expectation of survival with a good functional status for more than 1 year. ''([[EHS ESC guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])''<nowiki>"</nowiki> | ||
|} | |} | ||
| Line 27: | Line 27: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIb]] | | colspan="1" style="text-align:center; background:LemonChiffon"|[[EHS ESC guidelines classification scheme#Classification of Recommendations|Class IIb]] | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1. '''The usefulness of implantation of an ICD is of uncertain benefit to prolong meaningful survival in patients with a high risk of nonsudden death as predicted by frequent hospitalizations, advanced frailty, or comorbidities such as systemic malignancy or severe renal dysfunction. ''([[EHS ESC guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])''<nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1. '''The usefulness of implantation of an [[ICD]] is of uncertain benefit to prolong meaningful survival in patients with a high risk of nonsudden death as predicted by frequent hospitalizations, advanced frailty, or comorbidities such as systemic [[malignancy]] or severe renal dysfunction. ''([[EHS ESC guidelines classification scheme#Level of Evidence|''Level of Evidence: B'']])''<nowiki>"</nowiki> | ||
|} | |} | ||
Revision as of 18:56, 8 May 2014
|
ST Elevation Myocardial Infarction Microchapters |
|
Differentiating ST elevation myocardial infarction from other Diseases |
|
Diagnosis |
|
Treatment |
|
|
Case Studies |
|
ST elevation myocardial infarction implantable cardioverter defibrillator On the Web |
|
FDA on ST elevation myocardial infarction implantable cardioverter defibrillator |
|
CDC on ST elevation myocardial infarction implantable cardioverter defibrillator |
|
ST elevation myocardial infarction implantable cardioverter defibrillator in the news |
|
Blogs on ST elevation myocardial infarction implantable cardioverter defibrillator |
|
Directions to Hospitals Treating ST elevation myocardial infarction |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
2013 ACCF/AHA Guideline for the Management of Heart Failure (DO NOT EDIT)[1]
| Class I |
| "1. Implantable cardioverter-defibrillator (ICD) therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in selected patients with nonischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic guideline-directed medical therapy (GDMT), who have reasonable expectation of meaningful survival for more than 1 year. (Level of Evidence: A)" |
| "2. ICD therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in selected patients at least 40 days post-MI with LVEF of 30% or less and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year. (Level of Evidence: B)" |
| Class IIa |
| "1. To prevent sudden death, placement of an ICD is reasonable in patients with asymptomatic ischemic cardiomyopathy who are at least 40 days post-MI, have an LVEF of 30% or less, are on appropriate medical therapy, and have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: B)" |
| Class IIb |
| "1. The usefulness of implantation of an ICD is of uncertain benefit to prolong meaningful survival in patients with a high risk of nonsudden death as predicted by frequent hospitalizations, advanced frailty, or comorbidities such as systemic malignancy or severe renal dysfunction. (Level of Evidence: B)" |
References
- ↑ Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH; et al. (2013). "2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines". Circulation. 128 (16): 1810–52. doi:10.1161/CIR.0b013e31829e8807. PMID 23741057.